ethosuximide has been researched along with Down Syndrome in 3 studies
Ethosuximide: An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures.
ethosuximide : A dicarboximide that is pyrrolidine-2,5-dione in which the hydrogens at position 3 are substituted by one methyl and one ethyl group. An antiepileptic, it is used in the treatment of absence seizures and may be used for myoclonic seizures, but is ineffective against tonic-clonic seizures.
Down Syndrome: A chromosome disorder associated either with an extra chromosome 21 or an effective trisomy for chromosome 21. Clinical manifestations include hypotonia, short stature, brachycephaly, upslanting palpebral fissures, epicanthus, Brushfield spots on the iris, protruding tongue, small ears, short, broad hands, fifth finger clinodactyly, Simian crease, and moderate to severe INTELLECTUAL DISABILITY. Cardiac and gastrointestinal malformations, a marked increase in the incidence of LEUKEMIA, and the early onset of ALZHEIMER DISEASE are also associated with this condition. Pathologic features include the development of NEUROFIBRILLARY TANGLES in neurons and the deposition of AMYLOID BETA-PROTEIN, similar to the pathology of ALZHEIMER DISEASE. (Menkes, Textbook of Child Neurology, 5th ed, p213)
Excerpt | Relevance | Reference |
---|---|---|
"Agranulocytosis caused by ethosuximide is extremely rare in children." | 7.72 | Ethosuximide induced agranulocytosis. ( Imai, T; Itoh, S; Kawada, K; Kusaka, T; Nanba, M; Okada, H, 2003) |
" As a corollary, they also show that long-term use of ETH and GAB is devoid of adverse behavioral and cognitive effects." | 5.38 | Lack of behavioral and cognitive effects of chronic ethosuximide and gabapentin treatment in the Ts65Dn mouse model of Down syndrome. ( Corrales, A; Flórez, J; García, S; Martínez, P; Martínez-Cué, C; Rueda, N; Sharma, A; Vidal, V, 2012) |
"Agranulocytosis caused by ethosuximide is extremely rare in children." | 3.72 | Ethosuximide induced agranulocytosis. ( Imai, T; Itoh, S; Kawada, K; Kusaka, T; Nanba, M; Okada, H, 2003) |
" As a corollary, they also show that long-term use of ETH and GAB is devoid of adverse behavioral and cognitive effects." | 1.38 | Lack of behavioral and cognitive effects of chronic ethosuximide and gabapentin treatment in the Ts65Dn mouse model of Down syndrome. ( Corrales, A; Flórez, J; García, S; Martínez, P; Martínez-Cué, C; Rueda, N; Sharma, A; Vidal, V, 2012) |
"Children with Down syndrome are highly susceptible to infantile spasms." | 1.35 | Infantile spasms and Down syndrome: a new animal model. ( Aleem, IS; Ashraf, A; Cortez, MA; Kanawaty, A; Liu, CC; Sadeghnia, HR; Shen, L; Snead, OC; Stewart, L; Trepanier, CH; Wu, Y, 2009) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (66.67) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cortez, MA | 1 |
Shen, L | 1 |
Wu, Y | 1 |
Aleem, IS | 1 |
Trepanier, CH | 1 |
Sadeghnia, HR | 1 |
Ashraf, A | 1 |
Kanawaty, A | 1 |
Liu, CC | 1 |
Stewart, L | 1 |
Snead, OC | 1 |
Vidal, V | 1 |
García, S | 1 |
Martínez, P | 1 |
Corrales, A | 1 |
Flórez, J | 1 |
Rueda, N | 1 |
Sharma, A | 1 |
Martínez-Cué, C | 1 |
Imai, T | 1 |
Okada, H | 1 |
Nanba, M | 1 |
Kawada, K | 1 |
Kusaka, T | 1 |
Itoh, S | 1 |
3 other studies available for ethosuximide and Down Syndrome
Article | Year |
---|---|
Infantile spasms and Down syndrome: a new animal model.
Topics: 4-Butyrolactone; Animals; Anticonvulsants; Baclofen; Brain; Disease Models, Animal; Down Syndrome; E | 2009 |
Lack of behavioral and cognitive effects of chronic ethosuximide and gabapentin treatment in the Ts65Dn mouse model of Down syndrome.
Topics: Amines; Animals; Anticonvulsants; Behavior, Animal; Cognition; Cyclohexanecarboxylic Acids; Disease | 2012 |
Ethosuximide induced agranulocytosis.
Topics: Agranulocytosis; Anticonvulsants; Down Syndrome; Ethosuximide; Fever; Humans; Infant; Male | 2003 |